RenovoRx

RNXT · NASDAQ

$1.20+$0.04 (+3.45%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.16

Latest news

Press releaseOct 7, 8:30 AM ETGlobe Newswire
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
Press releaseOct 1, 8:30 AM ETGlobe Newswire
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
Press releaseSep 2, 8:30 AM ETGlobe Newswire
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
NewsAug 25, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Press releaseAug 25, 8:30 AM ETGlobe Newswire
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
Press releaseAug 21, 8:30 AM ETGlobe Newswire
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
Press releaseAug 20, 8:30 AM ETGlobe Newswire
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
NewsAug 12, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseAug 12, 4:05 PM ETGlobe Newswire
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
Press releaseAug 11, 8:30 AM ETGlobe Newswire
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
NewsAug 11, 8:01 AM ETVandana Singh
EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027
NewsAug 10, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseAug 6, 8:30 AM ETGlobe Newswire
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
Press releaseAug 4, 8:30 AM ETGlobe Newswire
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
Press releaseJul 29, 8:30 AM ETGlobe Newswire
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
Press releaseJun 4, 8:30 AM ETGlobe Newswire
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
Press releaseMay 19, 8:30 AM ETGlobe Newswire
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
NewsMay 14, 5:04 PM ET
RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript
Press releaseMay 14, 4:05 PM ETGlobe Newswire
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
NewsMay 14, 7:11 AM ET
Earnings Scheduled For May 14, 2026
Press releaseApr 29, 8:30 AM ETGlobe Newswire
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
Press releaseMar 30, 4:05 PM ETGlobe Newswire
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
NewsMar 30, 7:11 AM ET
Earnings Scheduled For March 30, 2026
Press releaseMar 20, 8:30 AM ETGlobe Newswire
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
Press releaseJan 30, 10:19 AM ETPRNewswire
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
Press releaseJan 20, 8:30 AM ETGlobe Newswire
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
NewsJan 12, 4:34 AM ETAvi Kapoor
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Press releaseJan 8, 12:08 PM ETGlobe Newswire
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
Press releaseDec 1, 8:30 AM ETGlobe Newswire
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
Press releaseNov 19, 8:30 AM ETGlobe Newswire
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th
NewsNov 14, 12:06 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
Press releaseNov 13, 4:05 PM ETGlobe Newswire
RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update
NewsNov 10, 7:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
Press releaseOct 27, 8:30 AM ETGlobe Newswire
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET
Press releaseOct 17, 9:50 AM ETPRNewswire
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Press releaseSep 11, 8:30 AM ETGlobe Newswire
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
NewsSep 8, 5:59 AM ETVishaal Sanjay
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
Press releaseAug 20, 8:30 AM ETBusiness Wire
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025
NewsAug 15, 1:07 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsAug 15, 8:10 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsAug 14, 4:18 PM ET
RenovoRx Announces The Independent Data Monitoring Committee For Its Ongoing Phase III TIGeR-PaC Trial Has Recommended To Continue The Study

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

12 Health Care Stocks Moving In Tuesday's Intraday Session

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

12 Health Care Stocks Moving In Wednesday's After-Market Session

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027

12 Health Care Stocks Moving In Monday's After-Market Session

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

Earnings Scheduled For May 14, 2026

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

Earnings Scheduled For March 30, 2026

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

12 Health Care Stocks Moving In Friday's Intraday Session

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

12 Health Care Stocks Moving In Monday's Pre-Market Session

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

RenovoRx Announces The Independent Data Monitoring Committee For Its Ongoing Phase III TIGeR-PaC Trial Has Recommended To Continue The Study